Released Aug 13, 2024, after the close
10-Q filed Aug 13, 2024, 44 days after period end · 0001390478-24-000015
Q2 2024 · 10-Q
Revenue—
Net Income-$7.47M-$7.47M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.13-$0.13 N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$7,621,000N/M
Operating Cash Flowderived-$9,682,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $1.90M |
| Net Income | -$7.47M | -$8.84M | -$8.41M | -$4.61M |
| EPS Diluted | -$0.13 | -$0.31 | -$0.41 | -$0.30 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR